Kelsey Klute is an Oncology physician affiliated with University of Nebraska Medical Center. OpenAlex indexes 120 publications with 3,275 citations (h-index 19); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Emile 42nd St
Omaha, NE 681980001
Telephone
402-559-5600Registry record last updated 18 Oct 2016.
Clinical trials
- Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection
Sponsor: University of Nebraska
- Blood Markers of Early Pancreas Cancer
Sponsor: University of Nebraska
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Partner Therapeutics, Inc.Program year20252 payments
- Ipsen Biopharmaceuticals, IncProgram year20251 payment
- Ipsen Biopharmaceuticals, IncProgram year20243 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
40.3%Serotonin-3 Receptor Antagonist15.2%Ondansetron Hcl100%Part D≥32 patientsProton pump inhibitor7.8%Omeprazole58%Pantoprazole Sodium42%Part D<11 patients+ 4 more classes in this area
Nervous system
39.1%Phenothiazine17%Prochlorperazine Maleate100%Part D≥35 patientsOpioid Agonist10.1%Oxycodone Hcl100%Part D≥15 patients+ 3 more classes in this area
Blood & clotting
13.4%Factor Xa inhibitor13.4%Eliquis100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Evolving Therapeutics for Resectable Esophageal Adenocarcinoma
Journal of the National Comprehensive Cancer Network
2025
Similar KOLs
Other experts from the same institution or the same specialty.
James Armitage, MD
University of Nebraska Medical Center
Julie Vose, MD
University of Nebraska Medical Center
Kathleen Moore, MD
University of Nebraska Medical Center
Ted Mikuls, MD
University of Nebraska Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”